Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients  by Cheung, Alan H.S. et al.
Kidney International, Vol. 41(1992), pp. 924—929
Simultaneous pancreas-kidney transplant versus kidney
transplant alone in diabetic patients
ALAN H. S. CHEUNG, DAVID E. R. SUTHERLAND, KRISTEN J. GILLINGHAM,
Lois E. MCHUGH, KAY C. MOUDRY-MUNNS, DAVID L. DUNN, JOHN S. NAJARIAN,
and ARTHUR J. MATAS
Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA
Simultaneous pancreas-kidney transplant versus kidney transplant
alone in diabetic patients. The decision for simultaneous pancreas-
kidney (SPK) versus kidney transplant alone (KTA) in diabetic patients
with renal failure depends on the potential risks and benefits for each
procedure. The purpose of this study was to compare the morbidity,
mortality, and renal allograft survival in diabetic patients who under-
went SPK versus KTA, and to discern the added risks associated with
pancreas transplantation. Between 7/1/86 and 9/30/90, 69 primary
cadaver SPK and 59 primary cadaver KTA were performed in type I
diabetic patients with chronic renal failure. Antilymphocyte globulin or
OKT3 was used for induction therapy, followed by standard triple
therapy (prednisone, azathioprine, and cyclosporine). Patient and graft
survivals were retrospectively analyzed. In addition, a detailed com-
parison of morbidity in those patients treated after 7/1/87 was performed
(53 SPK, 49 KTA). For those <45 years of age (65 SPK, 42 KTA), there
were no significant differences (P> 0.6) in the actuarial patient survival
at one year (SPK 92%, KTA 95%), or two years (SPK 89%, KTA 92%),
or actuarial rcnal allograft survival at one year (SPK 82%, KTA 83%) or
two years (SPK 77%, KTA 83%). However, for those >45 years old,
actuarial renal allograft survival was significantly higher (P < 0.03) in
the KTA group. The mean serum creatinine levels were similar at one
year (SPK 1.8, KTA 1.9 mg/d). Thirty-nine percent of KTA patients had
at least one rejection episode versus 72% for SPK (P < 0.02). The SPK
recipients were hospitalized longer during the initial admission (SPK
23.3 2.4 day, KTA 13.5 1.3 day, P < 0.001) and had a higher
number of readmissions (SPK 2.8 0.3, KTA 1.7 OF, P < 0.02).
Complications were more common in the SPK group in the following
categories: wound problems (SPK 23%, KTA 0%, P < 0.0002), urologic
problems (SPK 25%, KTA 8%, P < 0.06), bacterial infections (SPK
36%, KTA 12%, P < 0.02), fungal infections (SPK 45%, KTA 18%, P
<0.006) and urinary tract infections (UTI) (SPK 62%, KTA 27%, P <
0.0006). Gram positive bacteria and Candida were the prevalent patho-
gens in the U[Is in the SPK group. The incidence of pyelonephritis,
peripheral vascular disease, viral infections (including CMV), vascular,
GI, respiratory, cardiac, neurologic, or ophthalmologic problems were
not statistically different in the two groups. These data suggest that SPK
can be performed with patient and renal allograft survival rates equiv-
alent to KTA in uremic diabetic patients <45 years old, with a pancreas
survival rate of 73% at one and 67% at two years. However, patients
>45 are at increased risk and may have poorer renal allograft survival.
The increased early morbidity and hospital time should be considered
along with the benefits of improved quality of life with a functioning
pancreas when offering or selecting patients for SPK transplants.
Pancreas transplantation is being performed with increasing
frequency in patients with type I diabetes mellitus [1], particu-
larly those with end-stage renal failure who are obligated to
chronic immunosuppression in lieu of a kidney transplant [2].
A successful graft induces a normoglycemic, insulin-indepen-
dent state [3, 4], appears to have a beneficial effect on neurop-
athy [5, 6], and can prevent recurrence of diabetic nephropathy
in a renal allograft [7, 8]. Advanced retinopathy is not altered
[9], but patients with functioning pancreas grafts subjectively
report an improved quality of life with greater personal, social
and dietary freedom than while on exogenous insulin [10—13].
The results of pancreas transplantation have improved con-
siderably in recent years [14]. With simultaneous pancreas and
kidney transplantation (SPK) from cadaver donors, several
institutions have reported >90% patient survival and >70%
pancreas survival at one year [15—17]. The results with pancreas
transplants after a previous kidney have been less satisfactory,
with pancreas graft survival rates at one year in the 50—60%
range [151. However, that does not imply that a SPK transplant
is a better option, particularly if one can receive a kidney graft
from a living related donor to obtain the best long-term renal
allograft function [18].
For those without a living-related kidney donor, a SPK
transplant from a cadaver donor is attractive, but the decision
to proceed must not be based simply on knowledge of the
benefits or the potential benefits. The morbid risks associated
with the pancreas must also be considered, such as infection,
enhanced susceptibility to rejection episodes and the need for
additional ifnmunosuppression. Bladder drainage has evolved
as the most popular technique for management of pancreas graft
exocrine secretions [171, and the potential for urological com-
plications also exists [19, 20], Thus, we have retrospectively
reviewed our experience with primary cadaver SPK transplan-
tation since 1986 and made a comparison of morbidity, mortal-
ity, and renal allograft survival to diabetic patients who under-
went a primary cadaver kidney transplant alone (KTA) during
the same period.
This was not a randomized study. Diabetic patients with
uremia referred for therapy were advised to undergo a living
related kidney transplant if at all possible. For those without a
living related donor, the option of SPK transplant was pre-
sented. The patients who chose this option had to have insur-
ance coverage or be able to pay out of pocket for the additional
expense. Otherwise, a KTA was performed.
Methods
Patient population
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More than 400 pancreas transplants have been performed at
the University of Minnesota Hospital since 1978, the majority
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Table 1. Demographic information on patients transplanted between
7/1/87 and 9/30/90
SPK (N =53) KTA (N = 49)
Mean age (±sD) 36.7 6.5 39.8 10.1
Age stratificationa
45 years old 49 34
>45 years old 4 15
Number by sex
Male 31 25
Female 22 24
Number by race
Caucasian 52 47
N. Am. Native 0 1
Hispanic 1 0
Black 0 1
Mean No. of HLA-A, -B, 3.34 0.18 3.23 0.26
-DR -MM (±sD)
a P = 0.0062. No other cornparisons were statistically significant.
being solitary procedures. Between July 1, 1986 (inception of
the SPK program at our institution) and September 30, 1990, 69
primary cadaver SPK and 59 primary cadaver KTA were
performed. All recipients were adults who had type I diabetes
mellitus and chronic renal failure. We studied patient and graft
survival rates for the entire cohort. In addition, a detailed
comparison of morbidity in patients transplanted after 7/1/87
was performed (53 SPK, 49 KTA). The demographics of these
cohorts are given in Table 1. Mean age was similar, but the
proportion of patients >45 years old was significantly higher (P
= 0.0062) in the KTA group. The proportion of males was
higher in the SPK group, but the difference was not significant(P = 0.57). In both groups the overwhelming majority of
recipients were Caucasian. The mean number of HLA mis-
matches was similar in the two groups.
Surgical techniques
In KTA recipients, the kidney was placed in the right or left
iliac fossa via an extraperitoneal incision with vascular anasto-
moses to the iliac vessels. For the cohort transplanted after
7/1/87, the arterial anastomosis was end-to-side to the common
or external iliac artery in all 49 cases. Fourteen kidney grafts
had multiple arteries. The ureteroneocystostomy was by the
Lich technique in 18 cases, by the "single-stitch" [211 tech-
nique in 29 cases, and to a urinary bowel loop in two cases; the
Leadbetter-Politano technique was not employed.
In SPK recipients, both allografts were transplanted via a
midline incision, with the pancreas placed in the right and the
kidney in the left iliac fossa. The pancreas graft exocrine
secretions were drained into the bladder by a side-to-side
duodenocystostomy, except for two cases of segmental grafts in
which a ductocystostomy was constructed. The kidney arterial
anastomoses were end-to-side in 48 cases, and end-to-end to the
hypogastric artery in five cases; there were multiple vessels in
14 cases. The ureteroneocystostomy was by the Lich technique
in 14 cases, the "single-stitch" technique in six cases, and the
Leadbetter-Politano technique in 33 cases. Donor and recipient
operative techniques have been previously described [15, 22,
23].
Recipient immunosuppression
Minnesota antilymphocyte globulin (MALG, 20 mg/kg/day)
or OKT3 (5 mg/day) was used for induction therapy during the
immediate postranspiant period for both groups (7 days for
KTA, 10 to 14 days for SPK). Maintenance immunosuppression
for both groups included cyclosporine (8 mg/kg/day starting on
day 5, subsequently adjusted by HPLC), azathioprine (5 mg/kg/
day rapidly tapered to 2.5 mg/kg/day), and prednisone (2
mg/kg/day for SPK and 1 mg/kg/day for KTA tapered to 0.4
mg/kg/day by one month and 0.15 mg/kg/day by 1 year). Acute
rejection episodes were initially treated with increased pred-
nisone, followed by OKT3 (5 mg/kg) or MALG (20 mg/kg/day)
for 7 to 10 days if necessary.
For both groups, acute renal allograft rejection was defined as
an abrupt (>25%) rise in serum creatinine in the absence of
cyclosporine toxicity. A percutaneous kidney biopsy was usu-
ally performed to confirm the diagnosis. Acute rejection involv-
ing the pancreas allograft was defined as an abrupt drop in urine
amylase output to below 50% of baseline that was sustained for
at least 36 hours. Histologic confirmation of all pancreas
allograft rejection episodes was attempted by cystoscopically
directed biopsy unless there was concurrent histologically
confirmed renal allograft rejection. Recurrent allograft dysfunc-
tion was considered as an additional acute rejection episode
only if the onset of dysfunction occurred at least two weeks
after cessation of therapy for the preceding episode.
Data analysis
Patient and graft survival—Overall and by age. Actuarial
patient and graft survival rates were calculated for the overall
SPK versus KTA groups and according to whether the recipi-
ents were older or younger than 45 years of age. In the SPK
group, 65 recipients (94%) were 45 years and 4 were >45
years old. In the KTA group, 42 recipients (72%) were 45 and
17 were >45 years old (P = 0.001).
Pancreas allografts were considered functioning as long as
the recipients were insulin independent and euglycemic (plasma
glucose <180 mg/dl). Pancreas allograft loss was defined as
resumption of exogenous insulin for any reason, or death with
a functioning graft. Kidney allograft loss was defined as a return
to dialysis, death with a functioning graft, or for patients who
were not on dialysis at the time of transplantation, as an
elevation of serum creatinine to above the pre-transpiant base-
line level.
Morbidity. Wound complications: Any wound drainage,
bleeding, infection, lymphocele, or dehiscence. Urologic com-
plications: Any major or persistent bladder bleeding, ureter
stricture or obstruction, bladder leak or duodenal stump leaks.
Vascular complications: Renal artery or vein thrombosis or
stenosis, major bleeding, or renal infarction. Transplant pyelo-
nephritis: Parenchymal infection of the transplanted kidney
documented by culture, ultrasound and clinical exam. Gastro-
intestinal complications: Bleeding, perforation, infarction,
ischemia, ulcer, obstruction, or infection. Respiratory compli-
cations: Pulmonary infiltrate, infection, embolus, or ARDS.
Peripheral vascular problems: Arterial occlusion, venous
thrombosis, ischemia, claudication, gangrene, embolism, or
ulcer. Cardiac complications: Arrhythmias, CHF, MI, or isch-
emia. Neurologic complications: Aseptic meningitis, infection,
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TIA, stroke, seizure, or tumor. Eye problems: Glaucoma,
cataracts or bleeding. Infectiousproblems: CMV, herpes, shin-
gles, other viruses, acute or chronic bacteria, peritonitis, fungus
from any site.
Statistical analysis. Patient and graft survival rates were
calculated by the actuarial method and the significance of
differences were determined by the Gehan test [24]. For graft
survival rates, two analyses were performed. One included all
causes of graft loss (including death with a functioning graft);
and the other, causes of graft loss due to death were censored
(withdrawn from analysis as. functioning grafts at time of death).
Student's T-test was used to calculate the significance of
differences in mean values, and Fisher's exact test was used to
determine the significance of differences in incidences of events
between groups. P values <0.05 were considered significant.
Results
Patient survival
The overall actuarial patient survival was similar (P> 0.35) in
both groups, at one year being 87% in SPK and 95% in KTA,
and at two years being 86% in SPK and 92% in KTA patients.
In recipients 45 years old, patient survival rates were nearly
identical (P > 0.56), at one year being 92% in SPK and 95% in
KTA, and at two years 89% in SPK and 92% in KTA patients
(Fig. 1). However, for those >45, the patient survival rate was
significantly higher (P = 0.04) in the KTA group, being 94% at
one and two years versus 33% at these times in the SPK group.
Causes of death were similar in both groups, as shown in Table
2.
Graft survival
The overall actuarial kidney allograft survival was also sim-
ilar (P> 0.36) in both groups, at one year being 80% in SPK and
86% in KTA, and at two years being 75% in SPK and 86% in
KTA patients. For those 45 years old, again the kidney
allograft survival rates were nearly identical (P > 0.87), at one
year being 82% in SPK and 83% in KTA, and at two years being
77% in SPK and 83% in KTA patients (Fig. 2). However, for
those >45, kidney allograft survival was significantly better (P
Table 2. Causes of death in all patients transplanted between 7/1/86
and 9/30/90
100 ":;.,, KIA
SPK
80
60
40
N Recipient 1 yr
65 Kidney alone (KTA) 95%
20 65 Simult. pancreas/kidney (SPK) 92%
0
0 6 12 18 24 30 36
Patient survival, months post-transplant
Fig. 1. Recipient survival rates for cadaver simultaneous pancreas-
kidney (SPK) versus cadaver kidney transplant atone (KTA) in patients
<45 years old transplanted between 7/1/86 and 9/30/90. P = 0.57.
SPK(N=69) KTA(N=59)
Generalized sepsis 1(1.4%) 0
Viral sepsis 1(1.4%) 1(1.7%)
Myocardial infarction 1 (1.4%) 0
Malignancy 1(1.4%) 0
Cerebral vas. accident 1(1.4%) 1(1.7%)
Pulmonary emboli 1(1.4%) 1(1.7%)
Pulmonary problems 1 (1.4%) 0
Hyperkalemia 1(1.4%) 1(1.7%)
Aspergillosis 1(1.4%) 0
Other 0 1(1.7%)
Total 9 5
100
80
Kidney KIA
Kidney SPK
Pancreas SPK
N Graft category 1 yr
42 Kidney Tx alone (KTA) 83%
65 Kidney with simult pancreas (SPK) 82%
65 Pancreas with simult. kidney (SPK) 73%
60
40
20
0
0 6 12 18 24 30 36
Graft function, months post-transplant
Fig, 2, Kidney and pancreas graft survival rates for cadaver simulta-
neous pancreas-kidney (SPK) versus cadaver kidney transplant alone
(KTA) in patients <45 years old transplanted between 7/1/86 and
9/30/90. P = 0.87 for kidney comparisons.
= 0.02) in the KTA group, at one year being 38% in the SPK
versus 94% in the KTA recipients. This could be partially
explained by graft loss due to death since the death censored
kidney survival for those >45 years old at one year became 75%
for SPK and 100% for KTA (P = 0.04). The causes of renal
allograft loss are shown in Table 3.
The actuarial pancreas survival in the SPK group was 73% at
one year, and 67% at two years (Fig. 2).
Acute rejection
The SPK group experienced significantly more (P < 0.03)
episodes of first acute rejections (72%) than the KTA group
(39%). The mean number of acute rejection episodes per patient
was 1.0 0.1 in the SPK group versus 1.0 0.2 for the KTA
group (P = NS). The serum creatinine at one year was also
similar in both groups (1.8 0.1 SPK, 1.9 0.1 KTA,P NS).
Hospitalizations
Simultaneous pancreas-kidney recipients required signifi-
cantly longer (P = 0.001) hospitalization during their initial
operation (23,3 2.4 day) than the KTA recipients (13.5 1.3
day). The mean number of readmissions was also significantly
higher (P = 0.013) in the SPK (2.78 0.32) than the KTA group
Cheung et a!: SPK vs. KTA in diabetic patients 927
Table 3. Causes of renal allograft loss in all patients transplanted
between 7/1/86 and 9/30/90
SPK (N = 69) KTA (N 59)
Technical complication 0 I (1.7%)
Hyperacute rejection 1(1.5%) 0
Acute rejection 4 (5.9%) 0
Chronic rejection 2 (2.9%) 2 (3.4%)
Death 3 (4.4%) 3 (5.2%)
Malignancy 1(1.5%) 0
Acute tubular necrosis 0 1 (1.7%)
Thrombosis 2 (2.9%) 2 (3.4%)
Viral sepsis 1(1.5%) 0
Fungal sepsis 1(1.5%) 0
Other 0 1(1.7%)
Total 15 10
(1.71 0.27). However, the average hospital days per readmis-
sion were similar (29.8 4.7 day SPK, 21.3 4.7 day KTA,
P = NS).
Morbidity
Of the five major categories of morbidities assessed, three
were significantly different between SPK and KTA recipients.
Wound problems. The recipients of SPK had a significantly
greater (P = 0.0002) incidence of wound problems (23%) than
the KTA (0%) recipients, including superficial wound infections
(2), serous drainage without infection (3), lymphocele (1), deep
wound infections (2), and fascial dehiscence (2). Ten of these
patients required surgical treatment of these wound-related
problems.
Urologic problems. Urologic problems were higher in the
SPK (24%) than the KTA (8%) group, but not statistically
significant (P = 0.06). Of the 13 urologic complications in the
SPK group, there were 4 bleeding, 2 leaks, 3 strictures, and 3
obstructions; these were treated by cystoscopy (4), foley cath-
eter drainage (4), percutaneous dilation (1), operative repair (2),
and percutaneous stents (2). Of the 4 urologic complications in
the KTA group, there were 2 bleeding and 1 obstruction; all
managed cystoscopically.
Vascular problems. There were no significant differences in
the incidence of vascular complications in both groups (6%
SPK, 14% KTA). In the SPK group, there were 3 vascular
complications including renal artery thrombosis (1), renal vein
thrombosis (1), and infarction (1), all requiring nephrectomies.
In the KTA group, there were 7 vascular complications includ-
ing renal artery stenosis (3), renal vein thrombosis (2), and
infarction (2); 4 nephrectomies were required.
Infections. The SPK group had a statistically significant
greater (P < 0.02) incidence of bacterial (36% SPK, 12% KTA)
and fungal (45% SPK, 18% KTA) infections, but not viral
infections (32% SPK, 35% KTA, P = NS). The incidence of
cytomegalovirus (CMV) infections were similar in both groups
(32% SPK, 33% KTA, P = NS). A large number of bacterial
and fungal infections involved the urinary tract.
Urinary tract infections. The SPK recipients had a signifi-
cantly higher (P 0.0006) incidence of urinary tract infections
requiring antibiotic therapy (62%) than KTA recipients (27%).
Gram positive organisms (36% SPK, 16% KTA), Candida (30%
SPK, 8% KTA), and Eschericia coli (11% SPK, 4% KTA) were
predominant in the SPK group.
Reoperations. The incidence of reoperations was higher in
the SPK (19%) than the KTA (6%) group, but the difference was
not statistically significant (P = 0.075).
Others. There were no statistically significant differences in
the incidence of transplant pyelonephritis, gastrointestinal,
ophthalmologic, respiratory, peripheral vascular, cardiac, or
neurologic complications between each group.
Discussion
Our retrospective study shows the acute morbidity of ca-
daver simultaneous pancreas-kidney (SPK) transplantation to
be higher than that of cadaver kidney transplantation alone
(KTA) for type 1 diabetic patients with end-stage renal failure,
despite the fact that SPK patients tended to be younger. Patient
and renal allograft survival rates in recipients 45 were excel-
lent in both groups. However, patients >45 years may have a
higher mortality with the SPK transplant. We found that SPK
recipients experienced a greater number of first acute rejec-
tions, longer initial hospital stay, and a greater number of
readmissions, as well as increased wound problems, urologic
complications, bacterial and fungal infections (but not viral or
CMV), and urinary tract infections. These factors do not
necessarily offset the potential benefits of a successful pancreas
transplant, but should be considered when offering and select-
ing uremic diabetic patients for a SPK transplant.
Our finding that patient and kidney allograft survival are not
deleteriously affected by the addition of a pancreas in recipients
<45 years of age is in accordance with the experience of others.
Sollinger et al reported the University of Wisconsin experience
[171 with 30 patients who underwent SPK transplantation
between December, 1986 and April, 1988. The patients' mean
age (35 years) and mean duration of diabetes (22 years) were
remarkably similar to our group. Actuarial patient survival at
two years was 97%, and 83% of patients had functioning
allografts. Similar results have also been reported from the
University of Iowa [16] and the Mayo Clinic [25]. In addition,
SPK transplantation is associated with higher pancreas graft
survival rates than isolated pancreas transplantation in patients
in either the pre-uremic or post renal transplantation state [26].
In our series, the causes of death and kidney allograft loss
were essentially identical in each group. Despite our small
numbers, it seems patients >45 years old suffered a higher
mortality (2 of 4) with SPK transplants. These deaths were due
to sepsis and cerebral vascular accident 12 and 2 months after
transplantation, respectively. It is unclear whether age per se is
a relative risk, but elderly patients should be carefully screened
prior to SPK transplantation.
Endocrine pancreas function has been excellent for patients
with a successful SPK transplant. In addition to insulin-inde-
pendence, fasting blood glucose values and glycohemoglobin
percentages have remained in the normal range throughout the
period of follow-up [27], and OGTT performance has improved
with time [28].
Simultaneous pancreas-kidney (SPK) recipients experienced
more first acute rejection episodes than kidney transplant alone
(KTA) recipients. Sollinger et al [17] reported similar results; 23
of 30 SPK recipients experienced 49 episodes of acute rejection.
During a similar time period, 73 cadaver donor kidney recipi-
ents had 43 acute rejection episodes. Similarly, the Mayo Clinic
series [25] showed more episodes of acute rejection in the SPK
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group (27 versus 14, 25 patients per group); the mean number of
acute rejection episodes per patient was 1.5 1.0 for the SPK
versus 0.8 0.6 for the KTA group (P < 0.02).
Due to the tendency for more acute rejections, we used a
more aggressive induction immunosuppressive regimen in the
SPK than the KTA group, and also used more immunosuppres-
sion to treat acute rejection episodes. The increased immuno-
suppression may account for the higher morbidity in the SPK
group, particularly in terms of infections. Strategies to over-
come this problem are needed; one might be to use prospective
HLA matching. Our previous reports have shown a favorable
effect of DR matching on pancreas allograft survival rates [26,
291.
Prolonged immunosuppressive therapy, as well as the in-
creased incidence of acute rejection and higher complication
rates, are responsible for the increased hospitalization in the
SPK group. The Mayo Clinic has had a similar experience [25];
the mean hospitalization time for their SPK group was 71 34
days during the first year compared to 27 13 days for the KTA
recipients (P < 0.001). It is for this reason that overall medical
costs are higher for SPK recipients. With application of match-
ing, a reduction in immunosuppressive therapy may be possi-
ble. With additional experience, complications might be
avoided or better managed, possibly resulting in decreased
hospitalization. Currently, however, patients contemplating
SPK must be informed of longer initial hospitalization and a
higher cost.
Although the incidence of wound infection in our SPK
recipients was high (23%), no grafts were lost due to this
problem. A similar incidence of wound problems in SPK
recipients was reported by Schulak, Mayes and Hricik [30] at
Case Western Reserve University in Cleveland. They reported
wound problems in 44% of patients undergoing SPK transplan-
tation. All wound problems eventually resolved, and no grafts
were lost. At the Mayo Clinic, 61% of SPK grafts placed
extraperitoneally had wound complications [25]. Sollinger et al
[171 experienced surgical complications in 14 of 30 pancreas
recipients (35%) but have reduced the frequency of such
complications from 2.2 per patient to 0.3 per patient by chang-
ing to the duodenal "segment" technique originally described
by the group at Iowa [31]. Intraperitoneal placement of the
pancreas allograft has been associated with fewer wound com-
plications than with an extraperitoneal approach [32], but no
controlled studies have yet been performed.
In our series, the rate of bacterial and fungal infections were
highest in the SPK group, particularly involving the urinary
tract. The duodenocystostomy technique used for exocrine
drainage of the pancreas might predispose to a higher incidence
of urinary tract infections; however, nearly all were success-
fully treated with antibiotics without long-term sequelae. The
increased use of immunosuppression for prophylaxis and treat-
ment of acute rejections could explain the increased infection
rates. It is surprising that the viral (including CMV) infection
rates were similar between the two groups. This experience was
different at the Mayo Clinic where 10 of 18 SPK versus 2 of 18
KTA recipients were afflicted with CMV during the first post-
transplant year [25]. We did not specifically examine the
donor/recipient CMV serology status in our series, but we do
have an aggressive CMV prophylaxis protocol where all pan-
creas transplant recipients are treated with gancyclovir for 7 to
14 days along with hyperimmune globulin on postoperative
days 1, 4, and 7, followed by 12 weeks of oral acyclovir. This
intensive regimen may account for the relatively low CMV
infection rate in our series.
In summary, our data (and data in the literature) suggest the
following benefits and risks for patients undergoing SPK versus
KTA. The benefits of a SPK include correction of two diseases
(diabetes and renal failure) by a single operation, the ability to
use the kidney allograft to monitor for acute rejection that could
affect the pancreas (as opposed to a pancreas placed after a
KTA), protection from recurrent diabetic nephropathy, slowing
the progress of neuropathy, and the improved quality of life
from being insulin-independent and euglycemic. However,
there is no improvement in patient or renal allograft survival in
the short-term, and possibly an increased mortality in older
patients. Other risks include increased initial hospitalization
and readmissions, possibly more reoperations, higher cost, and
a higher incidence of bacterial, fungal and possibly CMV
infections.
Risk-versus-benefit should be considered when advising dia-
betic patients with renal failure whether to undergo a simulta-
neous pancreas-kidney or kidney transplantation alone. How-
ever, one must bear in mind that patients do not seek pancreas
transplants solely to slow the course of nephropathy; rather,
they also hope to improve metabolic control; gain freedom from
personal, social, and dietary restrictions; halt or reverse sec-
ondary complications of diabetes; and attain independence of
their lives. Simply making the decision of whether to undergo
pancreas transplantation gives patients the sense that they
finally have some control over their disease. Preliminary results
addressing quality of life at the University of Minnesota found
that patients with functioning pancreas grafts are generally
happy, feel healthier after the transplantation, are comfortable
with their decision to have the transplant, find the transplant
less demanding to live with than diabetes, and would encourage
others to undergo pancreas transplantation 1331. Because the
benefits include psychological and social effects as well as
physiological effects, the decision for a pancreas transplant
should ultimately rest with the patient.
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